aTyr Pharma (ATYR) Price & Analysis

Compare

2,580 Followers

ATYR Stock Chart & Stats

Day’s Range― - ―

52-Week Range$1.67 - $7.29

Previous CloseN/A

Volume346.43K

Average Volume (3M)5.40M

Market Cap

$503.65M

Enterprise Value$389.05M

Total Cash (Recent Filing)$17.22M

Total Debt (Recent Filing)$12.68M

Price to Earnings (P/E)―

Beta1.26

Next Earnings

Nov 06, 2025

EPS Estimate

-0.17

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-0.22

Shares Outstanding97,986,630

10 Day Avg. Volume4,130,516

30 Day Avg. Volume5,404,848

Financial Highlights & Ratios

PEG RatioN/A

Price to Book (P/B)N/A

Price to Sales (P/S)N/A

P/FCF RatioN/A

Enterprise Value/Market Cap0.77

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit-1.01K

Enterprise Value/Ebitda-5.62

Forecast

1Y Price Target

$19.44

Price Target Upside276.02% Upside

Rating ConsensusStrong Buy

Number of Analyst Covering9

Bulls Say, Bears Say

Bulls Say

Clinical TrialsEfzofitimod has shown encouraging Phase 1/2 results as a clinical proof of concept for pulmonary sarcoidosis, indicating a potential positive stock movement if Phase 3 results are favorable.

Growth PotentialA home run scenario could see the stock reaching high teens with a market cap approaching $2B, indicating substantial growth potential.

Market PositionEfzofitimod is the most advanced program for sarcoidosis, which is a sizable market with no approved targeted therapy and limited pipeline, suggesting a strong position for potential approval.

Bears Say

Investor ConcernsInvestors continue to question the tRNA-based mechanism, weaknesses in the preclinical data, and limitations of the small Ph 1/2 study.

Placebo EffectThe data appear to show a robust placebo effect, which would be a bad indicator for ATYR.

Statistical SignificanceThe probability of a negative scenario, where Phase 3 misses statistical significance, could result in a significant decrease in stock value.

aTyr Pharma News

aTyr Pharma price target raised to $17 from $9 at Jefferies

Jefferies analyst Roger Song raised the firm’s price target on aTyr Pharma (ATYR) to $17 from $9 and...

6d ago

ATYR

aTyr Pharma files $300M mixed securities shelf

16:24 EDT aTyr Pharma (ATYR) files $300M mixed securities shelf Published first on TheFly – the ultimate source...

21d ago

ATYR

aTyr Pharma reports Q2 EPS (22c), consensus (18c)

“With the recent completion of the last patient visit in our Phase 3 EFZO-FIT(TM) study of efzofitimod in...

21d ago

ATYR

aTyr Pharma Inc put volume heavy and directionally bearish

Bearish flow noted in aTyr Pharma (ATYR) Inc with 4,292 puts trading, or 2x expected. Most active are...

21d ago

ATYR

Optimistic Buy Rating for aTyr Pharma Amid Promising EFZO-FIT Trial Prospects

Leerink Partners analyst Faisal Khurshid reiterated a Buy rating on aTyr Pharma yesterday and set a price target...

7d ago

ATYR

Optimistic Outlook for aTyr Pharma Amidst Controversies: Analyst Highlights Potential in EFZO-FIT Study

Leerink Partners analyst Faisal Khurshid has reiterated their bullish stance on ATYR stock, giving a Buy rating on...

14d ago

ATYR

Optimistic Buy Rating for aTyr Pharma Amid Promising Phase 3 Data and Innovative Sarcoidosis Treatment Approach

H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on aTyr Pharma today and set a price target...

17d ago

ATYR

Promising Developments and Strong Financial Position Drive Buy Rating for aTyr Pharma

In a report released today, Soumit Roy from JonesTrading maintained a Buy rating on aTyr Pharma, with a...

20d ago

ATYR

aTyr Pharma: Strong Financials and Promising Therapeutic Candidate Drive Buy Rating

H.C. Wainwright analyst Joseph Pantginis reiterated a Buy rating on aTyr Pharma today and set a price target...

21d ago

ATYR

aTyr Pharma Reports Q2 2025 Financial Results

Atyr Pharma Inc. ( ($ATYR) ) has released its Q2 earnings. Here is a breakdown of the information...

21d ago

ATYR

Optimistic Outlook for aTyr Pharma’s Efzofitimod: High-Risk, High-Reward Potential in Phase 3 Trial

aTyr Pharma, the Healthcare sector company, was revisited by a Wall Street analyst yesterday. Analyst Faisal Khurshid from...

28d ago

ATYR

aTyr Pharma Inc put volume heavy and directionally bearish

Bearish flow noted in aTyr Pharma (ATYR) Inc with 10,964 puts trading, or 9x expected. Most active are...

1M ago

ATYR

aTyr Pharma management to meet with Cantor Fitzgerald

Meetings to be held in Denver July 30-31 hosted by Cantor Fitzgerald. Published first on TheFly – the...

1M ago

ATYR

High-Risk, High-Reward Opportunity in aTyr Pharma’s Efzofitimod Amid Upcoming Phase 3 Readout

Analyst Faisal Khurshid from Leerink Partners reiterated a Buy rating on aTyr Pharma and keeping the price target...

1M ago

ATYR

ATYR FAQ

What was aTyr Pharma’s price range in the past 12 months?

aTyr Pharma lowest stock price was $1.67 and its highest was $7.29 in the past 12 months.

What is aTyr Pharma’s market cap?

aTyr Pharma’s market cap is $503.65M.

When is aTyr Pharma’s upcoming earnings report date?

aTyr Pharma’s upcoming earnings report date is Nov 06, 2025 which is in 69 days.

How were aTyr Pharma’s earnings last quarter?

aTyr Pharma released its earnings results on Aug 07, 2025. The company reported -$0.22 earnings per share for the quarter, missing the consensus estimate of -$0.185 by -$0.035.

Is aTyr Pharma overvalued?

According to Wall Street analysts aTyr Pharma’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does aTyr Pharma pay dividends?

aTyr Pharma does not currently pay dividends.

What is aTyr Pharma’s EPS estimate?

aTyr Pharma’s EPS estimate is -0.17.

How many shares outstanding does aTyr Pharma have?

aTyr Pharma has 97,986,630 shares outstanding.

What happened to aTyr Pharma’s price movement after its last earnings report?

aTyr Pharma reported an EPS of -$0.22 in its last earnings report, missing expectations of -$0.185. Following the earnings report the stock price went up 1.145%.

Which hedge fund is a major shareholder of aTyr Pharma?

Currently, no hedge funds are holding shares in ATYR

aTyr Pharma Stock Smart Score

Outperform

Fundamentals

Return on Equity

-85.18%

Trailing 12-Months

Asset Growth

-4.16%

Trailing 12-Months

Top Smart Score Stocks >

Company Description

aTyr Pharma

aTyr Pharma, Inc. is a biopharmaceutical company focused on developing innovative therapies based on its proprietary protein-based platform, which is derived from the study of tRNA synthetases. The company primarily operates in the biotechnology sector, targeting rare diseases and inflammatory conditions. Its lead product candidate, ATYR1923, is being developed for the treatment of pulmonary sarcoidosis and other related disorders, highlighting the company's commitment to addressing unmet medical needs through advanced biopharmaceutical solutions.

aTyr Pharma (ATYR) Earnings & Revenues

Historic Earnings Reports

ATYR Stock 12 Month Forecast

Average Price Target

$19.44

▲(276.02% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"0":"$0","9":"$9","18":"$18","27":"$27","36":"$36"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":35,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$35.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":19.44,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$19.44</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":4.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$4.50</span>\n  </div></div>","useHTML":true}}],"tickPositions":[0,9,18,27,36],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Nov<br/>2024","6":"Feb<br/>2025","9":"May<br/>2025","12":"Aug<br/>2025","25":"Aug<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.7,7.030769230769231,9.361538461538462,11.692307692307693,14.023076923076925,16.353846153846156,18.684615384615384,21.015384615384615,23.346153846153847,25.676923076923078,28.00769230769231,30.33846153846154,32.66923076923077,{"y":35,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.7,5.833846153846154,6.9676923076923085,8.101538461538462,9.235384615384616,10.36923076923077,11.503076923076925,12.636923076923079,13.770769230769233,14.904615384615386,16.03846153846154,17.172307692307694,18.306153846153848,{"y":19.44,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,4.7,4.684615384615385,4.6692307692307695,4.653846153846154,4.638461538461539,4.6230769230769235,4.607692307692308,4.592307692307692,4.576923076923077,4.561538461538461,4.546153846153846,4.530769230769231,4.515384615384615,{"y":4.5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1.95,"date":1722470400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.87,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":1.72,"date":1727740800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.04,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.56,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.62,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.86,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.96,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":2.88,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 18,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":3.34,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.75,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 6, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":5.13,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 23,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 10, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.7,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 25,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 8, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >